On Friday, Sage Therapeutics Inc. (NASDAQ ... The company’s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&D workforce), including ...
Biogen proposed acquiring Sage Therapeutics for $7.22 per ... The company’s layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&D ...
Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
After a 2024 marred by a series of trial failures, Sage Therapeutics Inc. (Nasdaq ... said it would lay off more than 165 employees, or about 33% of its total workforce. Sage said toward the ...
Pharmaceutical Technology on MSN9d
Sage rejects Biogen’s $469m takeover bidSage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...
Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics ... off 165 employees – representing 55% of its research and development staff and 33% of its total workforce ...
Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following ... This included laying off 165 employees – representing 55% of its research and development staff and 33% of ...
In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $9.00. The company’s shares closed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback